Evidence map›Paper›PMID 38424632›Full record

ArticleJournal of translational medicine2024

Ubiquitylation of RUNX3 by RNA-binding ubiquitin ligase MEX3C promotes tumorigenesis in lung adenocarcinoma.

Zelai He, Huijun Zhang, Haibo Xiao, Xiangyu Zhang, Hongbo Xu, Ruifen Sun, Siwen Li

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Zelai He *Department of Radiation Oncology, The first affiliated hospital of Bengbu Medical University, Bengbu, 233000, Anhui, China.
Huijun Zhang *Department of Cardiothoracic Surgery, Huashan Hospital of Fudan University, Shanghai, 200040, China.
Haibo Xiao *Department of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Xiangyu ZhangDepartment of Pathology, Jining First People's Hospital, Jining Medical University, Jining, 272002, Shandong, China.
Hongbo XuDepartment of Radiation Oncology, The first affiliated hospital of Bengbu Medical University, Bengbu, 233000, Anhui, China. xuhongbo@bbmc.edu.cn.
Ruifen SunScience and Technology Division, Yunnan University of Chinese Medicine, Kunming, 650500, Yunnan, China. sunruifen@ynutcm.edu.cn.
Siwen LiDepartment of Thoracic Surgery, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, 511500, Guangdong, China. Dr_li952gyfly@yeah.net.ORCID 0000-0002-1045-3551
First Affiliated Hospital of Bengbu Medical College · CNFudan University · CNJining First People's Hospital · CNShanghai Jiao Tong University · CNSun Yat-sen University · CNYunnan University · CN

Funding

Bengbu Medical College Joint Research Project No. BYLK201810Bengbu Medical College Science Fund for "Excellent Young Teachers in 512 Talent Development Programme" No. BY51201314Natural Science Research Project of Anhui Educational Committee KJ2021A0781Natural Science Research Project of Anhui Educational Committee Nos. KJ2021A0692the First Affiliated Hospital of Bengbu Medical College Science Fund for Distinguished Young Scholars No. 2019BYYFYJQ04Translation Medicine Key Project of Bengbu Medical College No. BYTM2019013Yunnan Provincial Science and Technology Department-Applied Basic Research Joint Special Funds of Chinese Medicine No. 2019FF002(-011)
6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is the most common pathological type of lung cancer, but the early diagnosis rate is low. The RNA-binding ubiquitin ligase MEX3C promotes tumorigenesis in several cancers but its mechanism of action in LUAD is unclear. In this study, the biological activity of MEX3C was assessed in LUAD. MEX3C and RUNX3 mRNA levels in the tissues of LUAD patients were determined using reverse transcription‑quantitative PCR. The involvement of MEX3C in the growth and metastasis of LUAD cells was measured by EdU assay, CCK-8, colony formation, Transwell assay, TUNEL, and flow cytometry. Expression of apoptosis and epithelial-mesenchymal transition related proteins were determined using western blotting analysis. LUAD cells transfected with si-MEX3C were administered to mice subcutaneously to monitor tumor progression and metastasis. We found that MEX3C is strongly upregulated in LUAD tissue sections, and involved in proliferation and migration. A549 and H1299 cells had significantly higher levels of MEX3C expression compared to control HBE cells. Knockdown of MEX3C dramatically decreased cell proliferation, migration, and invasion, and accelerated apoptosis. Mechanistically, we demonstrate MEX3C induces ubiquitylation and degradation of tumor suppressor RUNX3. Moreover, RUNX3 transcriptionally represses Suv39H1, as revealed by RNA pull-down and chromatin immunoprecipitation assays. The in vivo mice model demonstrated that knockdown of MEX3C reduced LUAD growth and metastasis significantly. Collectively, we reveal a novel MEX3C-RUNX3-Suv39H1 signaling axis driving LUAD pathogenesis. Targeting MEX3C may represent a promising therapeutic strategy against LUAD.

Indexed as

Adenocarcinoma of LungLung NeoplasmsMicroRNAsAnimalsCell Line, TumorCell MovementCell ProliferationCell Transformation, NeoplasticCore Binding Factor Alpha 3 SubunitGene Expression Regulation, NeoplasticHumansLigasesMiceRNARNA-Binding ProteinsUbiquitinCore Binding Factor Alpha 3 SubunitLigasesMEX3C protein, humanMicroRNAsRNARNA-Binding ProteinsRunx3 protein, humanUbiquitinLUADMetastasisMEX3CRUNX3Suv39H1Tumor growth

Identifiers

PMID38424632
PMCPMC10905843
OpenAlexW4392296592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.